EyeGate Pharmaceuticals, Inc. (EYEG)
|Net Income (ttm)||-8.09M|
|Trading Day||May 7|
|Day's Range||3.90 - 4.09|
|52-Week Range||3.20 - 8.18|
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors
WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and ...
WALTHAM, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treati...
- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development -
WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treatin...
EyeGate Pharma shares doubled on Monday morning following the news of its acquisition of Austria's Panoptes Pharma. Zacks earlier boosted its target on EYEG stock to $15 a share.
Expands Pipeline Beyond Ophthalmology with PP-001 , a Clinical Stage, Best-in-Class DHODH Inhibitor
Investors Should Be Excited For EyeGate's Ocular Bandage
Eyegate: Speculative Buy For Their Better-Than-SOC Treatment In Corneal Wound Repair
Shares of EyeGate Pharmaceuticals Inc. rallied 95% in premarket trading on the news that the company's experimental eye-drop bandage performed better than the standard of care, which is a bandage contac...
Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE).
EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveit... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, EYEG's revenue was $12,059, a decrease of -99.55% compared to the previous year's $2.69 million. Losses were -$8.09 million, 14.0% more than in 2019.
According to 2 analysts, the average rating for EYEG stock is "Buy." The 12-month stock price forecast is 12.13, which is an increase of 208.65% from the latest price.